Shares of revenue are estimates for six months ended June 30, 2026, not figures from a filing.
Knee replacement implants
Artificial parts that replace all or part of a damaged knee, including components used in later repair or replacement procedures.
Hip replacement systems
Artificial parts that replace the ball and socket of the hip; some are fixed with bone cement and others are designed to attach directly to bone.
Sports medicine, extremities and trauma devices
Devices used to repair soft-tissue injuries, stabilize broken bones, and treat conditions in the foot, ankle, shoulder, elbow and wrist.
ROSA Robot
A surgical robot that helps surgeons position implants during certain knee, hip and shoulder procedures.
ZBEdge
A group of robotic and digital technologies that gathers information before, during and after surgery to help inform patient care.
Bone cement
Cement and related mixing and delivery products used to attach some orthopedic implants to bone.
Zimmer Biomet makes artificial knees and hips, as well as devices used to repair injuries to bones, joints, and surrounding soft tissue. Surgeons use its ROSA robot to help position implants during some operations. Hospitals and surgery centers buy products directly or through distributors and dealers; many products are kept on consignment for use when a procedure is scheduled.
Built from Zimmer Biomet Holdings, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$107.47+0.2%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Zimmer Biomet sells knee and hip replacement implants and other devices for bone and joint surgery to hospitals, surgery centers, and surgeons.
Just reported
From Zimmer Biomet's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$2.06B
+3.1% y/y
-5.2% q/q
Guided
—
No guide given
Actual
$1.00
-14% y/y
-2.9% q/q
Guided
—
No guide given
Actual
$307.6M
-12% y/y
-5.7% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Zimmer Biomet is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$130BA+
SYKStryker Corp.$121.3BA+
EWEdwards Lifesciences Corporation$60.8BA+
GEHCGE Healthcare Technologies Inc.$37.4BA
GKOSGlaukos Corp$14.6BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now AEWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade B
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Zimmer Biomet Holdings, Inc.’s grade history. The other 39 go back to November 2016.
